Abstract B066: Convergent cell-state programs characterize BRCA2 -reversion-independent resistance in pancreatic cancer
Most patients with pancreatic ductal adenocarcinoma (PDAC) present with advanced-stage disease, for which systemic therapy is the mainstay, highlighting the need to identify therapeutically vulnerable molecular tumor subgroups. Homologous recombination deficiency (HRD), arising from germline or somatic alterations in...